More importantly, our colony-formation assays showed that SB939 decreases the viability of primary CML progenitors and in combination with IM, can further reduce the viability of primary CML progenitors especially in those with the BIM deletion polymorphism that are more resistant to both SB939 and IM (compare Fig 4B to 4D). The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.